Indivior (NASDAQ:INDV) Reaches New 52-Week High - Here's Why

Key Points

• Indivior PLC's stock has reached a new 52-week high, trading at $21.49, reflecting an increase in investor interest and engagement.
• Analysts have upgraded Indivior's rating, with Craig Hallum increasing its price target to $22.00, and Wall Street Zen raising it to a strong-buy rating.
• The company's recent quarterly earnings report showed an EPS of $0.51, significantly surpassing estimates, indicating strong financial performance with revenues of $302 million.

Indivior PLC (NASDAQ:INDV - Get Free Report)'s stock price hit a new 52-week high on Monday . The stock traded as high as $21.49 and last traded at $21.22, with a volume of 3899789 shares changing hands. The stock had previously closed at $21.05.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on INDV shares. Craig Hallum raised their price objective on shares of Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Wall Street Zen raised Indivior from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Finally, Jefferies Financial Group started coverage on Indivior in a research note on Tuesday, July 22nd. They set a "buy" rating and a $20.00 target price on the stock. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $17.75.

Indivior Trading Up 0.8%

The firm has a market cap of $2.93 billion, a price-to-earnings ratio of 34.23 and a beta of 0.74. The firm has a 50 day moving average price of $14.85 and a 200-day moving average price of $11.90.

Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. The company had revenue of $302.00 million for the quarter, compared to the consensus estimate of $239.43 million. As a group, equities analysts expect that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in INDV. GF Fund Management CO. LTD. bought a new stake in shares of Indivior in the 4th quarter valued at approximately $36,000. Lazard Asset Management LLC acquired a new position in Indivior during the fourth quarter worth $57,000. Amalgamated Bank bought a new position in shares of Indivior during the second quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Indivior by 16.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company's stock valued at $71,000 after acquiring an additional 666 shares during the period. Finally, Schaper Benz & Wise Investment Counsel Inc. WI acquired a new stake in shares of Indivior in the 1st quarter valued at $95,000. Institutional investors own 60.33% of the company's stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.